Avandia Diabetes Drug Safety Questioned - New Vioxx?

[bestsynd]

Steven Nissen

(Best Syndication) Researchers in Ohio say that the common type-2 diabetes drug Avandia (rosiglitazone) increases the chance of heart attack and cardiovascular death. The maker of the drug, Glaxo Smith-Kline disputes the findings that were published in Monday’s New England Journal of Medicine (NEJM).

The company said in a statement that “GSK strongly disagrees with the conclusions reached in the NEJM article, which are based on incomplete evidence and a methodology that the author admits has significant limitations.” Even the journal admits to some weaknesses in the study, and conceded that the side effects could have been caused by chance.

Complete Best Syndication Article

[bestsynd]

(Best Syndication) Researchers in Europe say that people over 50 years of age with diabetes may not live as long as those without the disease, and may have fewer years without cardiovascular disease. The research is published in the June 11th issue of Archives of Internal Medicine.

The researchers used data from the Framingham Heart Study, a group of 5,209 men and women age 28 to 62 years recruited between 1948 and 1951 and followed for more than 46 years. "Having diabetes at age 50 years and older represents not only a significant increase in the risk of developing cardiovascular disease and mortality but also an important decrease in life expectancy and life expectancy free of cardiovascular disease," the authors wrote.

Complete Best Syndication Article

[bestsynd]

(Best Syndication) The Food and Drug Administration (FDA) is evaluating the safety of the diabetes drug Avandia Monday. A panel of experts is listening to both sides of the argument concerning the GlaxoSmithKlien (GSK) drug, whose stock dropped more the two percent on the news.

Earlier this month German researchers released a study that showed that the drug “might worsen complications of the disease such as weight gain, swelling, bone fractures and heart disease.” This was a review of an analysis of studies done back in May that suggested an increased risk of death from cardiovascular causes in patients taking the medication.

Complete Best Syndication Article

[bestsynd]

Type 2 Diabetes – Faulty Neurons affect Blood Glucose Levels



Type 2 diabetes is an inability to for the body to properly regulate blood glucose levels. There is a malfunction in the pancreatic beta cells and also the insulin is impaired which delivers the glucose to and from the liver, fat, and muscles. In a study from Beth Israel Deaconess Medical Center (BIDMC) along with Oregon Health & Science University found another abnormality that could also cause type 2 diabetes which is caused from glucose-sensing neurons that are not working properly. The study will be available in the online and printed journal of Nature.

“For many years we’ve known that subpopulations of neurons in the brain become ‘excited’ by glucose,” explains Bradford Lowell, MD, PhD, a researcher from the Division of Endocrinology, Diabetes and Metabolism at BIDMC and is also a Professor of Medicine at Harvard Medical School (HMS). “But we haven’t understood exactly how or why this is significant. With this study, we show that these neurons sense increases in glucose and then initiate responses aimed at returning blood-glucose levels to normal. This is the first demonstration that glucose-sensing by neurons plays an important role in responding to rising blood glucose levels.”

More about the study on Type 2 diabetes

[bestsynd]

(Best Syndication) Experts say that a combination aerobic and resistance exercise is best for controlling blood sugar, compared to either one separately. The research conducted in Canada involved 251 adult participants between the ages of 39 and 70 who did not exercise regularly and had type-2 diabetes.

The scientists randomly assigned the participants to four groups. One group performed a 45 minute aerobic exercise three times per week while another performed a strength training exercise three times per week. Those two groups saw an improved glycermic / blood sugar level.

Combination Weight Lifting and Aerobics Is better than either alone

[bestsynd]

Diabetes Drug Does Not Increase Rate Of Death By Heart Attack – Sulfonylureas Drugs Not Dangerous – Mayo Clinic Researchers



(Best Syndication) Researchers at the Mayo Clinic say that sulfonylureas drugs used to treat patients with diabetes do not reduce the risk of surviving a heart attack. The pills are used to increase the release of insulin, thus lowering blood sugar. Since diabetes mellitus is a growing problem, it is important to determine which drugs work and which do not.

Diabetes mellitus is commonly refereed to as diabetes, but includes a syndrome of conditions including a disordered metabolism and high blood sugar. The cause could be from either low levels of insulin or a resistance to the effects of insulin, or a combination of both. Symptoms include excessive urination and a excessive thirst. Some patients may experience blurred vision, but not all sufferers experience symptoms.

Complete Article

[Guitarras Reyes]

Sounds good....until the very next Mayo clinic conducts further research on the above implications and publishes sulfonylureas "may" indeed cause heart attacks after all. Stay tuned. Its just my prediction.



It really is no wonder some Americans behave both neurotic AND paranoid.
_________________
www.myspace.com/suejacobsband
Hecho en E.U.A. COMING SOON!

[bestsynd]

Avandia Drug Gets Black Box Warning Because of Increased Risk for Heart Attack And Failure In Type II 2 Diabetes Patients Helps Actos



(Best Syndication) The GlaxoSmithKline diabetes drug Avandia will have a new black box warning added to their product. The Black Box warning is the most severe warning a drug can have, and this is the second warning for Avandia. This second warning may be a little watered-down because it states that the results are not conclusive.

The FDA is warning doctors and patients that Avandia may cause heart attacks. The federal watchdog agency says doctors should monitor “people with type 2 diabetes who have underlying heart disease or who are at high risk of heart attack.” According to Lawyers and Settlements, this will give the company a “seven-year reprieve from further scrutiny.”

Avandia Black Box Warning Helps Actos

[bestsynd]

Type 2 Diabetes Drug Avandia Linked To Osteoporosis and Bone Loss – GlaxoSmithKline Says Their Study Did Not Show Fractures



(Best Syndication) Researchers believe that the diabetes drug Avandia may cause bone loss and long-term use may speed up osteoporosis. The thinning of the bones is dangerous and could lead to fatal fractures. The study published in the December 2nd issue of Nature Medicine suggests that usage of rosiglitazone in the treatment of type II diabetes may cause osteoporosis.

The maker of the drug, GlaxoSmithKline (GSK), disputes the osteoporosis finding. The company said in a statement today that their ADOPT studies showed no increase in spine or hip fractures which are associated with osteoporosis. The company says they will be looking further into the subject.

More on the Avandia Osteoporosis Study

[bestsynd]

Type of Fat Cells Determines Diabetes Risk – Subcutaneous Fat Can Reduce Risk For Type-1 Diabetes – Belly Fat Less An Issue



(Best Syndication News) Harvard researchers say that a little extra fat around the body in locations other than the abdomen area may reduce the insulin resistance and improve insulin sensitivity. This was an unexpected finding because belly-fat has long been associated with an increased risk for type-2 diabetes.

Not all fat is the same, according to Dr. C. Ronald Kahn, Head of the Joslin Research Section on Obesity and Hormone Action and the Mary K. Iacocca Professor of Medicine at Harvard Medical School. “This points to a new opportunity to find substances made by subcutaneous fat that may actually be good for glucose metabolism,’’ Kahn said.

Belly and Skin Fat and Diabetes

[bestsynd]

Intensive Diabetes Therapy Worsened Cardiovascular Event Risk In Some Patients



(Best Syndication News) New findings suggest that “intensive” control of blood glucose does not reduce the risk of death from cardiovascular events (CVE) in some patients. The results of the study were released at the 68th Scientific Sessions of the American Diabetes Association (ADA). The researchers evaluated the results from two randomized trials: the ACCORD trial and the ADVANCE trial.

"While we found that intensive treatment of patients with type 2 diabetes suggested some benefits from glucose control, it did not reach significance for a reduction in the primary endpoint - a composite of specified cardiovascular disease events - in this population," said William C. Duckworth, MD, Director of Diabetes Research, Carl T. Hayden VA Medical Center in Phoenix, Professor of Clinical Medicine, University of Arizona, and Co-Chair of the trial.

Intensive Diabetes therapy and cardiovascular risk